| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |

*
Molecular and Cellular Nephrology, Institute of Medical Sciences and
Department of Internal Medicine, Tokai University School of Medicine, Isehara,
Kanagawa, Japan
Service de Nephrologie, Université
Catholique de Louvain, Brussels, Belgium.
Correspondence to Dr. Toshio Miyata, Molecular and Cellular Nephrology, Institute of Medical Sciences and Department of Internal Medicine, Tokai University School of Medicine, Bohseidai, Isehara, Kanagawa 259-1143, Japan. Phone: 81-463-93-1936; Fax: 81-463-93-1938; E-mail: t-miyata{at}is.icc.u-tokai.ac.jp
Abstract. The accumulation in uremic plasma of reactive carbonyl
compounds (RCO) derived from both carbohydrates and lipids ("carbonyl
stress") contributes to uremic toxicity by accelerating the advanced
glycation and lipoxidation of proteins. It was previously demonstrated that
OPB-9195
[(±)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide]
inhibited the in vitro formation of advanced glycation end products
(AGE) in uremic plasma. This study was designed to elucidate the mechanism of
action of OPB-9195 by further delineating the AGE and advanced lipoxidation
end product (ALE) precursors targeted by this drug. The inhibitory effects of
OPB-9195 on the formation of two AGE (N
-carboxymethyllysine and
pentosidine) on bovine serum albumin incubated with various AGE precursors
were examined. Inhibition of N
-carboxymethyllysine and
pentosidine formation with OPB-9195 was more efficient than with
aminoguanidine. OPB-9195 also proved effective in blocking the carbonyl amine
chemical processes involved in the formation of two ALE
(malondial-dehyde-lysine and 4-hydroxynonenal-protein adduct). The efficiency
of OPB-9195 was similar to that of aminoguanidine. When glucose-based
peritoneal dialysis fluid was incubated in the presence of OPB-9195, a similar
inhibition of AGE formation was observed. The direct effect of OPB-9195 on
major glucose-derived RCO in peritoneal dialysis fluids was then evaluated.
The effects of OPB-9195 could be accounted for by its ability to trap RCO. The
concentrations of three major glucose-derived RCO (glyoxal, methylglyoxal, and
3-deoxy-glucosone) were significantly lower in the presence of OPB-9195 than
in its absence. Aminoguanidine had a similar effect. In conclusion, OPB-9195
inhibits both AGE and ALE formation, probably through its ability to trap RCO.
OPB-9195 might prove to be a useful tool to inhibit some of the effects of
RCO-related uremic toxicity.
This article has been cited by other articles:
![]() |
J. M. Bohlender, S. Franke, G. Stein, and G. Wolf Advanced glycation end products and the kidney Am J Physiol Renal Physiol, October 1, 2005; 289(4): F645 - F659. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Nakamura and T. Niwa Pyridoxal Phosphate and Hepatocyte Growth Factor Prevent Dialysate-Induced Peritoneal Damage J. Am. Soc. Nephrol., January 1, 2005; 16(1): 144 - 150. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Culbertson, E. I. Vassilenko, L. D. Morrison, and Keith. U. Ingold Paradoxical Impact of Antioxidants on Post-Amadori Glycoxidation: COUNTERINTUITIVE INCREASE IN THE YIELDS OF PENTOSIDINE AND N{epsilon}-CARBOXYMETHYLLYSINE USING A NOVEL MULTIFUNCTIONAL PYRIDOXAMINE DERIVATIVE J. Biol. Chem., October 3, 2003; 278(40): 38384 - 38394. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Miyata, C. van Ypersele de Strihou, Y. Ueda, K. Ichimori, R. Inagi, H. Onogi, N. Ishikawa, M. Nangaku, and K. Kurokawa Angiotensin II Receptor Antagonists and Angiotensin-Converting Enzyme Inhibitors Lower In Vitro the Formation of Advanced Glycation End Products: Biochemical Mechanisms J. Am. Soc. Nephrol., October 1, 2002; 13(10): 2478 - 2487. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kurokawa, M. Nangaku, A. Saito, R. Inagi, and T. Miyata Current Issues and Future Perspectives of Chronic Renal Failure J. Am. Soc. Nephrol., January 1, 2002; 13(90001): S3 - 6. [Full Text] [PDF] |
||||
![]() |
G. Xiang, R. Schinzel, A. Simm, G. Munch, K. Sebekova, M. Kasper, T. Niwa, C. Schmitz, and A. Heidland Advanced glycation end products (AGEs)-induced expression of TGF-{beta}1 is suppressed by a protease in the tubule cell line LLC-PK1 Nephrol. Dial. Transplant., August 1, 2001; 16(8): 1562 - 1569. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. Price, P. M. Rhett, S. R. Thorpe, and J. W. Baynes Chelating Activity of Advanced Glycation End-product Inhibitors J. Biol. Chem., December 21, 2001; 276(52): 48967 - 48972. [Abstract] [Full Text] [PDF] |
||||
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673